A Phase 3 interventional study of LY2963016 and Lantus in Diabetes Mellitus, Type 1, sponsored by Eli Lilly and Company. Completed at 52 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-09.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is one of 8 that started in 2011, is one of 18 in phase 3, and was the 30th registered.
3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 536 is above the median of 40 across 2,822 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company: 4 open now, 6 under way, 4 of them phase 3. Of 66 finished, 49 (74%) have results posted.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 6th largest by enrollment of the 72 interventional ones that give a count, is the only one that started in 2011, is one of 23 in phase 3, and was the 15th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 1 studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 75 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
Drug: LY2963016 · Drug: Insulin Lispro
Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
Drug: Lantus · Drug: Insulin Lispro
Administered subcutaneously
Administered subcutaneously
Administered subcutaneously
Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A which provides an estimate of a participant's blood sugar control over a 6- to 12-week period. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline, Endpoint (up to 24 weeks)
Change From Baseline in Insulin Antibody Levels
Blood samples are collected from participants and percentage of insulin antibody binding was measured to determine the insulin antibody levels. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline, 6 weeks and 12 weeks and Endpoints (up to 24 weeks and up to 52 weeks)
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A which provides an estimate of a participant's blood sugar control over a 6- to 12-week period. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline, 6 weeks and 12 weeks and 24 weeks and 36 weeks and 52 weeks and Endpoint (up to 52 weeks)
7-Point Self-Monitored Blood Glucose (SMBG) Profiles
7-point SMBG measurements are completed at the following timepoints: Morning (AM) Pre-Meal, AM Post-Prandial (PP), Midday (MD) Pre-Meal, MD PP, Evening (EV) Pre-Meal, Bed Time and 0300 hours. PP glucose is measured 2 hours (hrs) after the start of the meal. Values for the 7-point SMBG profiles were averaged over the three 7-point SMBG profiles during 2-week period prior to each visit. If only 1 of the 3 days of data was collected, then the value of the 1 day was used. If only 2 of the 3 days of data were collected, then the average of the 2 days was used. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline and Endpoints [up to 24 weeks (wk) and up to 52 weeks]
Glycemic Variability of Fasting Blood Glucose
Glycemic variability is the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning premeal blood glucose value from the 7-point self-monitoring blood glucose (SMBG) profiles. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline and Endpoints (up to 24 weeks and up 52 weeks)
Change From Baseline in Body Weight
Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline, 6 weeks and 12 weeks and 18 weeks and Endpoints (up to 24 weeks and up to 52 weeks)
Adult Low Blood Sugar Survey (ALBSS)
ALBSS contains 33 items, with each item scored on a 5-point response scale: 0 (never) to 4 (almost always). Items are categorized in 2 domains: Behavior (or avoidance) Items 1 to 15 and Worry (or affect) Items 16 to 33. Behavior Total Score (TS) range is 0 to 60 and Worry TS range is 0 to 72. Higher scores on "Behavior" items (related to avoidance of hypoglycemia) reflect greater awareness and/or effort of the participant to prevent low blood sugar. Higher scores on "Worry" items (related to worries about low blood sugar and its consequences) reflect greater participant concern about having low blood sugar. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline and 24 weeks and Endpoint (up to 52 weeks)
Insulin Treatment Satisfaction Questionnaire (ITSQ)
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. Items divided into 5 domains: Inconvenience of Regimen \[(IR) 5 items: scores range 5-35\], Lifestyle Flexibility \[(LF) 3 items: scores range 3-21\], Glycemic Control \[(GC) 3 items: scores range 3-21\], Hypoglycemic Control \[(HC) 5 items: scores range 5-35\], Insulin Delivery Device \[(IDD) 6 items: scores range 6-42\]. ITSQ Total Overall Scores range from 22-154. Data presented are the transformed score on a scale of 0-100, where transformed score=100×\[(7-raw score)/6\]. Higher scores indicate better treatment satisfaction. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Baseline and 24 weeks and Endpoint (up to 52 weeks)
Insulin Dose Per Body Weight (U/kg) (Total and by Component [Basal and Bolus (Lispro)])
Total daily insulin dose was adjusted for body weight \[units of insulin/kilogram/day (U/kg/day)\]. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Endpoints [up to 24 weeks (wk) and up to 52 weeks]
Insulin Dose - Units [Total and by Component [Basal and Bolus (Lispro)])
Units of insulin taken daily were presented. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
Time frame: Endpoints [up to 24 weeks (wk) and up to 52 weeks]
Percentage of Participants With Hemoglobin A1c (HbA1c) <7.0% and HbA1c ≤6.5%
HbA1c is the glycosylated fraction of hemoglobin A which provides an estimate of a participant's blood sugar control over a 6- to 12-week period. The percentage of participants with Hemoglobin A1c (HbA1c) \<7.0% or HbA1c ≤6.5% is calculated as the number of participants with an HbA1c level of the cut-off value (\<7.0% or ≤6.5%) divided by the number of participants treated, then multiplied by 100.
Time frame: Baseline and 6 weeks and 12 weeks and 24 weeks and 36 weeks and 52 weeks and Endpoints (up to 24 weeks and up to 52 weeks)
Incidence of Hypoglycemic Events
Incidence of hypoglycemic events is defined as the number of hypoglycemic events. A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has a blood glucose (BG) concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\], even if it was not associated with signs, symptoms, or treatment consistent with current guidelines \[American Diabetes Association (ADA) 2005\]. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.
Time frame: Baseline through 24 weeks (wk) and 52 weeks
Rate Per 30 Days of Hypoglycemic Events
The rate of hypoglycemic events per 30 days is defined as the total number of events between visits divided by the actual number of days between visits, and then multiplied by 30 days. A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose (BG) concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\], even if it was not associated with signs, symptoms, or treatment consistent with current guidelines (ADA 2005). Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.
Time frame: Baseline through 24 weeks (wk) and 52 weeks
| Milestone | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Started | 269 | 267 |
| Received at least 1 dose of study drug | 268 | 267 |
| Completed | 253 | 256 |
| Not completed | 16 | 11 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Withdrawal by subject | 10 | 5 |
| Milestone | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Started | 253 | 256 |
| Completed | 245 | 245 |
| Not completed | 8 | 11 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 3 |
HbA1c is the glycosylated fraction of hemoglobin A which provides an estimate of a participant's blood sugar control over a 6- to 12-week period. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| percentage of glycosylated hemoglobin | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c) | -0.352 ± 0.053 | -0.460 ± 0.054 |
Blood samples are collected from participants and percentage of insulin antibody binding was measured to determine the insulin antibody levels. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| percentage of insulin antibody binding | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Change at 6 weeks (n=31, 38) | 0.30 ± 0.33 | -0.12 ± 0.33 |
| Change at 12 weeks (n=27, 36) | 0.02 ± 0.39 | -0.38 ± 0.39 |
| Change at Endpoint, up to 24 weeks (n=37, 47) | 0.47 ± 0.45 | 0.09 ± 0.44 |
| Change at Endpoint, up to 52 weeks (n=40, 47) | 0.87 ± 0.58 | 0.06 ± 0.56 |
HbA1c is the glycosylated fraction of hemoglobin A which provides an estimate of a participant's blood sugar control over a 6- to 12-week period. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline HbA1c, treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| percentage of glycosylated hemoglobin | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Change at 6 weeks (n=265, 265) | -0.369 ± 0.038 | -0.362 ± 0.039 |
| Change at 12 weeks (n=261, 262) | -0.359 ± 0.049 | -0.472 ± 0.049 |
| Change at 24 weeks (n=256, 258) | -0.383 ± 0.053 | -0.481 ± 0.053 |
| Change at 36 weeks (n=253, 254) | -0.349 ± 0.056 | -0.408 ± 0.056 |
| Change at 52 weeks (n=248, 246) | -0.302 ± 0.059 | -0.306 ± 0.060 |
| Change at Endpoint, up to 52 weeks (n=267, 267) | -0.256 ± 0.057 | -0.276 ± 0.058 |
7-point SMBG measurements are completed at the following timepoints: Morning (AM) Pre-Meal, AM Post-Prandial (PP), Midday (MD) Pre-Meal, MD PP, Evening (EV) Pre-Meal, Bed Time and 0300 hours. PP glucose is measured 2 hours (hrs) after the start of the meal. Values for the 7-point SMBG profiles were averaged over the three 7-point SMBG profiles during 2-week period prior to each visit. If only 1 of the 3 days of data was collected, then the value of the 1 day was used. If only 2 of the 3 days of data were collected, then the average of the 2 days was used. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| millimoles per liter (mmol/L) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Baseline-AM Pre-Meal (n=266, 264) | 8.37 ± 0.18 | 8.19 ± 0.18 |
| Baseline-AM 2 hrs PP (n=263, 262) | 8.93 ± 0.19 | 9.41 ± 0.19 |
| Baseline-MD Pre-Meal (n=266, 265) | 7.86 ± 0.16 | 8.14 ± 0.16 |
| Baseline-MD 2 hrs PP (n=264, 264) | 9.12 ± 0.18 | 8.81 ± 0.18 |
| Baseline-EV Pre-Meal (n=264, 264) | 8.87 ± 0.19 | 8.82 ± 0.19 |
| Baseline-Bed Time (n=266, 264) | 9.26 ± 0.20 | 9.37 ± 0.20 |
| Baseline-0300 hrs (n=262, 257) | 8.27 ± 0.18 | 8.37 ± 0.18 |
| Endpoint, up to 24 wk-AM Pre-Meal (n=266, 264) | 7.98 ± 0.20 | 7.81 ± 0.20 |
| Endpoint, up to 24 wk-AM 2 hrs PP (n=263, 262) | 8.75 ± 0.20 | 8.50 ± 0.21 |
| Endpoint, up to 24 wk-MD Pre-Meal (n=266, 265) | 7.81 ± 0.19 | 7.84 ± 0.20 |
| Endpoint, up to 24 wk-MD 2 hrs PP (n=264, 264) | 8.50 ± 0.21 | 8.41 ± 0.21 |
| Endpoint, up to 24 wk-EV Pre-Meal (n=264, 264) | 8.82 ± 0.21 | 8.61 ± 0.22 |
| Endpoint, up to 24 wk-Bed Time (n=266, 264) | 8.61 ± 0.22 | 9.11 ± 0.22 |
| Endpoint, up to 24 wk-0300 hrs (n=262, 257) | 7.93 ± 0.20 | 8.38 ± 0.20 |
| Endpoint, up to 52 wk- AM Pre-Meal (n=266, 264) | 8.03 ± 0.20 | 8.29 ± 0.21 |
| Endpoint, up to 52 wk-AM 2 hrs PP (n=263, 262) | 8.55 ± 0.21 | 8.88 ± 0.21 |
| Endpoint, up to 52 wk-MD Pre-Meal (n=266, 265) | 7.96 ± 0.19 | 7.99 ± 0.19 |
| Endpoint, up to 52 wk-MD 2 hrs PP (n=264, 264) | 8.61 ± 0.21 | 8.74 ± 0.21 |
| Endpoint, up to 52 wk-EV Pre-Meal (n=264, 264) | 8.37 ± 0.21 | 8.38 ± 0.21 |
| Endpoint, up to 52 wk-Bed Time (n=266, 264) | 8.57 ± 0.21 | 9.06 ± 0.21 |
| Endpoint, up to 52 wk-0300 hrs (n=262, 257) | 8.22 ± 0.21 | 8.43 ± 0.22 |
Glycemic variability is the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning premeal blood glucose value from the 7-point self-monitoring blood glucose (SMBG) profiles. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| millimoles per liter (mmol/L) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Baseline | 2.51 ± 0.12 | 2.68 ± 0.12 |
| Endpoint, up to 24 weeks | 2.25 ± 0.14 | 2.29 ± 0.14 |
| Endpoint, up to 52 weeks | 2.08 ± 0.13 | 2.34 ± 0.13 |
Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| kilogram (kg) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Change at 6 weeks (n=265, 265) | 0.45 ± 0.09 | 0.42 ± 0.09 |
| Change at 12 weeks (n=261, 261) | 0.59 ± 0.13 | 0.48 ± 0.13 |
| Change at 18 weeks (n=258, 260) | 0.72 ± 0.15 | 0.55 ± 0.15 |
| Change at Endpoint, up to 24 weeks (n=268, 267) | 0.66 ± 0.17 | 0.42 ± 0.17 |
| Change at Endpoint, up to 52 weeks (n=268, 267) | 0.93 ± 0.21 | 0.59 ± 0.21 |
ALBSS contains 33 items, with each item scored on a 5-point response scale: 0 (never) to 4 (almost always). Items are categorized in 2 domains: Behavior (or avoidance) Items 1 to 15 and Worry (or affect) Items 16 to 33. Behavior Total Score (TS) range is 0 to 60 and Worry TS range is 0 to 72. Higher scores on "Behavior" items (related to avoidance of hypoglycemia) reflect greater awareness and/or effort of the participant to prevent low blood sugar. Higher scores on "Worry" items (related to worries about low blood sugar and its consequences) reflect greater participant concern about having low blood sugar. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| units on a scale | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Baseline-Behavior TS (n=265, 263) | 13.63 ± 0.54 | 12.99 ± 0.54 |
| 24 weeks-Behavior TS (n=255, 257) | 12.73 ± 0.66 | 12.53 ± 0.66 |
| Endpoint, up to 52 weeks-Behavior TS (n=265, 263) | 13.19 ± 0.62 | 13.03 ± 0.62 |
| Baseline-Worry TS (n=265, 263) | 16.01 ± 0.83 | 14.81 ± 0.83 |
| 24 weeks-Worry TS (n=255, 258) | 15.39 ± 1.08 | 14.27 ± 1.08 |
| Endpoint, up to 52 weeks-Worry TS (n=265, 263) | 15.18 ± 1.03 | 14.93 ± 1.05 |
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. Items divided into 5 domains: Inconvenience of Regimen \[(IR) 5 items: scores range 5-35\], Lifestyle Flexibility \[(LF) 3 items: scores range 3-21\], Glycemic Control \[(GC) 3 items: scores range 3-21\], Hypoglycemic Control \[(HC) 5 items: scores range 5-35\], Insulin Delivery Device \[(IDD) 6 items: scores range 6-42\]. ITSQ Total Overall Scores range from 22-154. Data presented are the transformed score on a scale of 0-100, where transformed score=100×\[(7-raw score)/6\]. Higher scores indicate better treatment satisfaction. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| units on a scale | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| IR-Baseline (n=264, 263) | 74.62 ± 1.31 | 75.39 ± 1.32 |
| IR-24 weeks (n=254, 258) | 79.32 ± 1.62 | 78.76 ± 1.62 |
| IR-Endpoint, up to 52 weeks (n=264, 263) | 79.50 ± 1.60 | 80.44 ± 1.62 |
| LF-Baseline (n=264, 263) | 63.19 ± 1.47 | 62.38 ± 1.47 |
| LF-24 weeks (n=254, 258) | 64.18 ± 1.90 | 63.34 ± 1.90 |
| LF-Endpoint, up to 52 weeks (n=264, 263) | 63.25 ± 1.86 | 64.16 ± 1.88 |
| GC-Baseline (n=264, 263) | 64.44 ± 1.34 | 64.34 ± 1.34 |
| GC-24 weeks (n=254, 258) | 72.99 ± 1.62 | 71.73 ± 1.62 |
| GC-Endpoint, up to 52 weeks (n=264, 263) | 70.15 ± 1.67 | 69.24 ± 1.69 |
| HC-Baseline (n=264, 263) | 70.20 ± 1.15 | 70.81 ± 1.15 |
| HC-24 weeks (n=254, 258) | 70.40 ± 1.48 | 71.42 ± 1.48 |
| HC-Endpoint, up to 52 weeks (n=264, 263) | 70.46 ± 1.47 | 71.72 ± 1.49 |
| IDD-Baseline (n=262, 262) | 75.22 ± 1.20 | 76.75 ± 1.20 |
| IDD-24 weeks (n=252, 258) | 79.77 ± 1.42 | 79.36 ± 1.42 |
| IDD-Endpoint, up to 52 weeks (n=262, 262) | 79.46 ± 1.37 | 79.75 ± 1.39 |
| ITSQ Total-Baseline (n=264, 262) | 70.80 ± 0.99 | 71.39 ± 1.00 |
| ITSQ Total-24 weeks (n=253, 258) | 74.46 ± 1.23 | 74.23 ± 1.24 |
| ITSQ Total-Endpoint, up to 52 weeks (n=264, 262) | 73.94 ± 1.25 | 74.48 ± 1.26 |
Total daily insulin dose was adjusted for body weight \[units of insulin/kilogram/day (U/kg/day)\]. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| U/kg/day | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Endpoint, up to 24 wk-Basal Insulin (n=268, 266) | 0.371 ± 0.011 | 0.358 ± 0.011 |
| Endpoint, up to 24 wk-Bolus Insulin (n=264, 266) | 0.352 ± 0.015 | 0.346 ± 0.016 |
| Endpoint, up to 24 wk-Total Insulin (n=264, 266) | 0.723 ± 0.021 | 0.704 ± 0.021 |
| Endpoint, up to 52 wk-Basal Insulin (n=268, 266) | 0.379 ± 0.012 | 0.361 ± 0.012 |
| Endpoint, up to 52 wk-Bolus Insulin (n=264, 266) | 0.369 ± 0.016 | 0.370 ± 0.016 |
| Endpoint, up to 52 wk-Total Insulin (n=264, 266) | 0.748 ± 0.022 | 0.731 ± 0.022 |
Units of insulin taken daily were presented. Least Squares (LS) means were calculated by analysis of covariance (ANCOVA) and adjusted for baseline hemoglobin A1c (HbA1c), treatment and time of basal insulin injection (daytime, evening/bedtime) and country.
| units of insulin per day (U/day) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Endpoint, up to 24 wk-Basal Insulin (n=268, 266) | 27.773 ± 0.970 | 26.049 ± 0.987 |
| Endpoint, up to 24 wk-Bolus Insulin (n=264, 266) | 26.337 ± 1.347 | 25.069 ± 1.362 |
| Endpoint, up to 24 wk-Total Insulin (n=264, 266) | 54.118 ± 1.948 | 51.154 ± 1.970 |
| Endpoint, up to 52 wk-Basal Insulin (n=268, 266) | 28.463 ± 1.073 | 26.404 ± 1.091 |
| Endpoint, up to 52 wk-Bolus Insulin (n=264, 266) | 27.800 ± 1.329 | 27.098 ± 1.344 |
| Endpoint, up to 52 wk-Total Insulin (n=264, 266) | 56.255 ± 2.008 | 53.454 ± 2.031 |
HbA1c is the glycosylated fraction of hemoglobin A which provides an estimate of a participant's blood sugar control over a 6- to 12-week period. The percentage of participants with Hemoglobin A1c (HbA1c) \<7.0% or HbA1c ≤6.5% is calculated as the number of participants with an HbA1c level of the cut-off value (\<7.0% or ≤6.5%) divided by the number of participants treated, then multiplied by 100.
| percentage of participants | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| HbA1c- at Baseline <7.0 % (n=267, 267) | 28.8 | 19.5 |
| HbA1c- at Baseline ≤6.5% (n=267, 267) | 13.9 | 12.0 |
| HbA1c- at 6 weeks <7.0% (n=265, 265) | 37.0 | 26.4 |
| HbA1c- at 6 weeks ≤6.5% (n=265, 265) | 21.1 | 14.3 |
| HbA1c- at 12 weeks <7.0% (n=261, 262) | 33.3 | 29.8 |
| HbA1c- at 12 weeks ≤6.5% (n=261, 262) | 19.9 | 15.3 |
| HbA1c- at 24 weeks <7.0% (n=256, 258) | 34.0 | 33.3 |
| HbA1c- at 24 weeks ≤6.5% (n=256, 258) | 19.9 | 19.0 |
| HbA1c- at 36 weeks <7.0% (n=253, 254) | 32.0 | 28.3 |
| HbA1c- at 36 weeks ≤6.5% (n=253, 254) | 15.4 | 18.5 |
| HbA1c- at 52 weeks <7.0% (n=248, 246) | 29.8 | 27.2 |
| HbA1c- at 52 weeks ≤6.5% (n=248, 246) | 15.3 | 14.6 |
| HbA1c- Endpoint, up to 24 weeks <7.0% (n=267, 267) | 34.5 | 32.2 |
| HbA1c- Endpoint, up to 24 weeks ≤6.5% (n=267, 267) | 20.2 | 18.4 |
| HbA1c- Endpoint, up to 52 weeks <7.0% (n=267, 267) | 30.3 | 25.1 |
| HbA1c- Endpoint, up to 52 weeks ≤6.5% (n=267, 267) | 15.7 | 13.5 |
Incidence of hypoglycemic events is defined as the number of hypoglycemic events. A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has a blood glucose (BG) concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\], even if it was not associated with signs, symptoms, or treatment consistent with current guidelines \[American Diabetes Association (ADA) 2005\]. Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.
| events | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Total Events with BG ≤70 mg/dL,if available-24 wk | 10411 | 10976 |
| Total Events with BG ≤70 mg/dL,if available-52-wk | 19541 | 20852 |
| Severe Events-24 wk | 6 | 10 |
| Severe Events-52 wk | 13 | 16 |
| Nocturnal Events with BG ≤70 mg/dL-24 wk | 2217 | 2249 |
| Nocturnal Events with BG ≤70 mg/dL-52 wk | 4105 | 4485 |
The rate of hypoglycemic events per 30 days is defined as the total number of events between visits divided by the actual number of days between visits, and then multiplied by 30 days. A hypoglycemic event is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has blood glucose (BG) concentration of ≤ 70 milligrams/deciliter \[mg/dL (3.9 millimoles/liter (mmol/L)\], even if it was not associated with signs, symptoms, or treatment consistent with current guidelines (ADA 2005). Severe hypoglycemia is defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions (these episodes may be associated with sufficient neuroglycopenia to induce seizure or coma; also, BG measurements may not be available during such an event). Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking.
| hypoglycemic events per 30 days | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| Total Events with BG ≤70 mg/dL, if available-24 wk | 7.10 ± 6.35 | 7.32 ± 6.58 |
| Severe Events-24 wk | 0.00 ± 0.04 | 0.01 ± 0.04 |
| Nocturnal Events with BG ≤70 mg/dL-24 wk | 1.50 ± 1.93 | 1.51 ± 1.77 |
| Total Events with BG ≤70 mg/dL, if available-52 wk | 6.33 ± 5.64 | 6.56 ± 6.12 |
| Severe Events-52 wk | 0.01 ± 0.04 | 0.01 ± 0.04 |
| Nocturnal Events with BG ≤70 mg/dL-52 wk | 1.32 ± 1.66 | 1.42 ± 1.60 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 + Insulin Lispro | — | 20/268 (7.5%) | 161/268 (60.1%) |
| Lantus + Insulin Lispro | — | 24/267 (9%) | 158/267 (59.2%) |
| Event | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 13/268 | 12/267 |
| PancytopeniaBlood and lymphatic system disorders | 0/268 | 1/267 |
| Hypertrophic cardiomyopathyCardiac disorders | 0/268 | 1/267 |
| Acute tonsillitisInfections and infestations | 0/268 | 1/267 |
| GastroenteritisInfections and infestations | 0/268 | 1/267 |
| Maternal exposure during pregnancyInjury, poisoning and procedural complications | 0/268 | 1/267 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/268 | 1/267 |
| KetoacidosisMetabolism and nutrition disorders | 0/268 | 1/267 |
| Exostosis of jawMusculoskeletal and connective tissue disorders | 0/268 | 1/267 |
| Gliomatosis cerebriNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/268 | 1/267 |
| Event | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro |
|---|---|---|
| NasopharyngitisInfections and infestations | 43/268 | 45/267 |
| Upper respiratory tract infectionInfections and infestations | 22/268 | 21/267 |
| DiarrhoeaGastrointestinal disorders | 12/268 | 10/267 |
| Back painMusculoskeletal and connective tissue disorders | 10/268 | 9/267 |
| InfluenzaInfections and infestations | 5/268 | 9/267 |
| HypertensionVascular disorders | 9/268 | 5/267 |
| BronchitisInfections and infestations | 4/268 | 8/267 |
| SinusitisInfections and infestations | 7/268 | 8/267 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/268 | 8/267 |
| GastroenteritisInfections and infestations | 8/268 | 7/267 |
All randomized participants who received at least 1 dose of study drug.
| Age, Continuous(years) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| Mean | 40.96 ± 13.65 | 41.37 ± 13.25 | 41.16 ± 13.44 |
| Sex: Female, Male(Participants) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| Female | 113 | 112 | 225 |
| Male | 155 | 155 | 310 |
| Ethnicity (NIH/OMB)(Participants) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| Hispanic or Latino | 11 | 10 | 21 |
| Not Hispanic or Latino | 177 | 170 | 347 |
| Unknown or Not Reported | 80 | 87 | 167 |
| Race (NIH/OMB)(Participants) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| American Indian or Alaska Native | 11 | 12 | 23 |
| Asian | 49 | 51 | 100 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 2 | 11 |
| White | 197 | 201 | 398 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| United States | 99 | 96 | 195 |
| Hungary | 14 | 16 | 30 |
| Mexico | 17 | 19 | 36 |
| Greece | 15 | 13 | 28 |
| Belgium | 12 | 11 | 23 |
| Poland | 18 | 17 | 35 |
| Romania | 18 | 16 | 34 |
| Germany | 26 | 28 | 54 |
| Japan | 49 | 51 | 100 |
| Baseline Hemoglobin A1c (HbA1c)(percentage of glycosylated hemoglobin) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| Mean | 7.75 ± 1.13 | 7.79 ± 1.03 | 7.77 ± 1.08 |
| Time of Basal Insulin Injection(participants) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| Daytime | 51 | 48 | 99 |
| Evening/Bedtime | 217 | 219 | 436 |
| Body Weight(kilograms (kg)) | LY2963016 + Insulin Lispro | Lantus + Insulin Lispro | Total |
|---|---|---|---|
| Mean | 75.80 ± 16.76 | 74.77 ± 15.36 | 75.29 ± 16.07 |
The record gives a start of Aug 2011, a primary completion of Aug 2012 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 2 months after primary completion. A results delay was requested in Sep 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine